Advertisement

Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

  • Martha Rodríguez-Morán
    Affiliations
    Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico
    Search for articles by this author
  • Luis E. Simental-Mendía
    Affiliations
    Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico
    Search for articles by this author
  • Claudia I. Gamboa-Gómez
    Affiliations
    Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico
    Search for articles by this author
  • Fernando Guerrero-Romero
    Correspondence
    Address correspondence to Fernando Guerrero-Romero, MD, PhD, Canoas 100, Col. Los Angeles, 34067 Durango, Durango, Mexico.
    Affiliations
    Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico
    Search for articles by this author
      The objective of the study was to evaluate the efficacy of oral magnesium supplementation in the improvement of metabolic syndrome (MetS) and its components. This is a randomized double-blind, placebo-controlled clinical trial that enrolled 198 individuals with MetS and hypomagnesemia who were randomly allocated to receive either 30 mL of magnesium chloride 5% solution, equivalent to 382 mg of elemental magnesium (n = 100), or placebo solution (n = 98), daily for 16 weeks. Serum magnesium levels <1.8 mg/dL defined hypomagnesemia. At final conditions, a total of 48 (48%) and 76 (77.5%) individuals had MetS in the magnesium and placebo groups (P = 0.01), respectively. At baseline, percent of individuals with 3, 4, and 5 criteria of MetS in the magnesium group were 60.0%, 37.0%, and 3.0%, respectively, and in the control group 55.1%, 35.7%, and 9.2%, respectively. Between basal and final conditions, changes in the components of MetS were significantly higher in the magnesium than placebo groups: −3.6 ± 3.3 mmHg, P = 0.001 for systolic blood pressure; −5.5 ± 1.7 mmHg, P = 0.005 for diastolic blood pressure; −12.4 ± 3.6 mg/dL, P < 0.005 for fasting glucose; −61.2 ± 24 mg/dL, P = 0.003 for triglycerides; and 0.9 ± 0.4 mg/dL, P = 0.06 for high-density lipoprotein cholesterol. Magnesium supplementation improves MetS by reducing blood pressure, hyperglycemia, and hypertriglyceridemia.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alberti K.G.
        • Eckel R.H.
        • Grundy S.M.
        • et al.
        Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
        Circulation. 2009; 120: 1640-1645
        • He K.
        • Song Y.
        • Belin R.J.
        • et al.
        Magnesium intake and metabolic syndrome: epidemiologic evidence to date.
        J Cardiometabol Syndr. 2006; 1: 351-355
        • Paolisso G.
        • Barbagallo M.
        Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium.
        Am J Hypertens. 1997; 10: 346-355
        • Suarez A.
        • Pulido N.
        • Casla A.
        • et al.
        Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats.
        Diabetologia. 1995; 38: 1262-1270
        • Belin R.J.
        • He K.
        Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome.
        Magnes Res. 2007; 20: 107-129
        • Touyz R.M.
        Role of magnesium in the pathogenesis of hypertension.
        Mol Aspects Med. 2003; 24: 107-136
        • Pearson P.J.
        • Evora P.R.
        • Seccombe J.F.
        • et al.
        Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations.
        Ann Thorac Surg. 1998; 65: 967-972
        • Simental-Mendía L.E.
        • Sahebkar A.
        • Rodríguez-Morán M.
        • Guerrero-Romero F.
        A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control.
        Pharmacol Res. 2016; 111: 272-282
        • Kass L.
        • Weekes J.
        • Carpenter L.
        Effect of magnesium supplementation on blood pressure: a meta-analysis.
        Eur J Clin Nutr. 2012; 66: 411-418
        • Simental-Mendía L.E.
        • Simental-Mendía M.
        • Sahebkar A.
        • Rodríguez-Morán M.
        • Guerrero-Romero F.
        Effect of magnesium supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials.
        Eur J Clin Pharmacol. 2017; 73: 525-536
        • Dibaba D.T.
        • Xun P.
        • Fly A.D.
        • Yokota K.
        • He K.
        Dietary magnesium intake and risk of metabolic syndrome: a meta-analysis.
        Diabet Med. 2014; 31: 1301-1309
        • Ju S.Y.
        • Choi W.S.
        • Ock S.M.
        • Kim C.M.
        • Kim D.H.
        Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression.
        Nutrients. 2014; 6: 6005-6019
        • Sarrafzadegan N.
        • Khosravi-Boroujeni H.
        • Lotfizadeh M.
        • Pourmogaddas A.
        • Salehi-Abargouei A.
        Magnesium status and the metabolic syndrome: a systematic review and meta-analysis.
        Nutrition. 2016; 32: 409-417
        • Guerrero-Romero F.
        • Jaquez-Chairez F.O.
        • Rodríguez-Morán M.
        Magnesium in metabolic syndrome: a review based on randomized, double-blind clinical trials.
        Magnes Res. 2016; 29: 146-153
        • Lima de Souza E Silva Mde L.
        • Cruz T.
        • Rodrigues L.E.
        • et al.
        Magnesium replacement does not improve insulin resistance in patients with metabolic syndrome: a 12-week randomized double-blind study.
        J Clin Med Res. 2014; 6: 456-462
        • American Heart Association Nutrition Committee
        • Lichtenstein A.H.
        • Appel L.J.
        • Brands M.
        • et al.
        Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart association Nutrition Committee.
        Circulation. 2006; 114: 82-96
        • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
        Third report of the National cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Mejía-Rodríguez F.
        • Shamah-Levy T.
        • Villalpando S.
        • García-Guerra A.
        • Méndez-Gómez Humarán I.
        Iron, zinc, copper and magnesium deficiencies in Mexican adults from the National health and Nutrition Survey 2006.
        Salud Publica Mex. 2013; 55: 275-284
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        • Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
        National Heart, Lung, and blood Institute; National high blood pressure Education Program Coordinating Committee. Seventh report of the joint National Committee on prevention, Detection, evaluation, and treatment of high blood pressure.
        Hypertension. 2003; 42: 1206-1252
        • Guerrero-Romero F.
        • Simental-Mendía L.E.
        • Hernández-Ronquillo G.
        • Rodriguez-Morán M.
        Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial.
        Diabete Metab. 2015; 41: 202-207
        • Mejía J.
        • Fajardo A.
        • Gomez A.
        • Cuevas M.
        • Herandez D.
        • Garduño J.
        El tamaño de muestra: Un enfoque práctico en la investigación clínica pediátrica.
        Bol Med Hosp Infant Mex. 1995; 52: 382-391
        • Jee S.H.
        • Miller 3rd, E.R.
        • Guallar E.
        • Singh V.K.
        • Appel L.J.
        • Klag M.J.
        The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials.
        Am J Hypertens. 2002; 15: 691-696
        • Cosaro E.
        • Bonafini S.
        • Montagnana M.
        • et al.
        Effects of magnesium supplements on blood pressure, endothelial function and metabolic parameters in healthy young men with a family history of metabolic syndrome.
        Nutr Metab Cardiovasc Dis. 2014; 24: 1213-1220
        • Coudray C.
        • Rambeau M.
        • Feillet-Coudray C.
        • et al.
        Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach.
        Magnes Res. 2005; 18: 215-223
        • Ford E.S.
        • Li C.
        • McGuire L.C.
        • Mokdad A.H.
        • Liu S.
        Intake of dietary magnesium and the prevalence of the metabolic syndrome among U.S. adults.
        Obesity (Silver Spring). 2007; 15: 1139-1146
        • Mirmiran P.
        • Shab-Bidar S.
        • Hosseini-Esfahani F.
        • Asghari G.
        • Hosseinpour-Niazi S.
        • Azizi F.
        Magnesium intake and prevalence of metabolic syndrome in adults: Tehran Lipid and Glucose Study.
        Public Health Nutr. 2012; 15: 693-701
        • Wang J.
        • Persuitte G.
        • Olendzki B.C.
        • et al.
        Dietary magnesium intake improves insulin resistance among non-diabetic individuals with metabolic syndrome participating in a dietary trial.
        Nutrients. 2013; 5: 3910-3919
        • Rodríguez-Morán M.
        • Guerrero-Romero F.
        Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial.
        Diabetes Care. 2003; 26: 1147-1152